Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.79M | 11.18M | 10.46M | 29.18M | 24.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.79M | 11.18M | 10.46M | 29.18M | 24.12M |
| Cost of Revenue | -- | -- | -- | 7.98M | 4.44M |
| Gross Profit | 11.79M | 11.18M | 10.46M | 21.20M | 19.69M |
| SG&A Expenses | 16.07M | 17.07M | 24.35M | 17.14M | 18.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.32M | 46.96M | 54.83M | 53.86M | 58.42M |
| Operating Income | -31.53M | -35.78M | -44.37M | -24.68M | -34.30M |
| Income Before Tax | -35.56M | -41.78M | -50.83M | 7.00M | -37.05M |
| Income Tax Expenses | -33.00K | -188.00K | 52.00K | -259.00K | 9.00K |
| Earnings from Continuing Operations | -35.52M | -41.59M | -50.88M | 7.26M | -37.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.52M | -41.59M | -50.88M | 7.26M | -37.06M |
| EBIT | -31.53M | -35.78M | -44.37M | -24.68M | -34.30M |
| EBITDA | -31.34M | -35.57M | -43.94M | -24.35M | -33.31M |
| EPS Basic | -1.87 | -2.95 | -3.62 | 0.52 | -2.66 |
| Normalized Basic EPS | -1.17 | -1.83 | -2.25 | -1.43 | -1.66 |
| EPS Diluted | -1.87 | -2.95 | -3.62 | 0.51 | -2.66 |
| Normalized Diluted EPS | -1.17 | -1.83 | -2.25 | -1.41 | -1.66 |
| Average Basic Shares Outstanding | 18.95M | 14.09M | 14.06M | 13.98M | 13.95M |
| Average Diluted Shares Outstanding | 18.95M | 14.09M | 14.06M | 14.24M | 13.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |